Carmela Ciardullo
Oncology R&D, AstraZeneca
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.
Journal: ESMO open
Published: October 27, 2025
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.
Journal: British journal of cancer
Published: July 14, 2025
Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 29, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 04, 2025
Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition.
Journal: International journal of molecular sciences
Published: December 16, 2022
Low BACH2 Expression Predicts Adverse Outcome in Chronic Lymphocytic Leukaemia.
Journal: Cancers
Published: October 27, 2021
DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia.
Journal: International journal of molecular sciences
Published: September 23, 2020
Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments.
Journal: British journal of haematology
Published: July 01, 2015
Last Updated: 09/26/2026